- Home
- CURI vs IFRX Comparison
CURI vs IFRX Comparison
Compare CURI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- IFRX
- Stock Information
- Founded
- CURI N/A
- IFRX 2007
- Country
- CURI United States
- IFRX Germany
- Employees
- CURI N/A
- IFRX N/A
- Industry
- CURI Movies/Entertainment
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- IFRX Health Care
- Exchange
- CURI Nasdaq
- IFRX Nasdaq
- Market Cap
- CURI 144.8M
- IFRX 65.8M
- IPO Year
- CURI N/A
- IFRX 2017
- Fundamental
- Price
- CURI $5.08
- IFRX $1.67
- Analyst Decision
- CURI Strong Buy
- IFRX Strong Buy
- Analyst Count
- CURI 2
- IFRX 4
- Target Price
- CURI $5.40
- IFRX $8.50
- AVG Volume (30 Days)
- CURI 943.7K
- IFRX 254.3K
- Earning Date
- CURI 05-06-2025
- IFRX 05-07-2025
- Dividend Yield
- CURI 2.85%
- IFRX N/A
- EPS Growth
- CURI N/A
- IFRX N/A
- EPS
- CURI N/A
- IFRX N/A
- Revenue
- CURI $54,223,000.00
- IFRX $140,242.00
- Revenue This Year
- CURI $14.45
- IFRX $106.72
- Revenue Next Year
- CURI $10.55
- IFRX $66.89
- P/E Ratio
- CURI N/A
- IFRX N/A
- Revenue Growth
- CURI N/A
- IFRX 30.90
- 52 Week Low
- CURI $0.98
- IFRX $0.82
- 52 Week High
- CURI $5.30
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CURI 78.21
- IFRX 61.82
- Support Level
- CURI $3.21
- IFRX $1.42
- Resistance Level
- CURI $5.30
- IFRX $1.71
- Average True Range (ATR)
- CURI 0.37
- IFRX 0.18
- MACD
- CURI 0.18
- IFRX 0.03
- Stochastic Oscillator
- CURI 90.27
- IFRX 69.23
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.